This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CXADR · Western blot design guide
CXADR Western Blot Planning Guide
Plan a CXADR Western blot around the catalog-observed 40 kDa band, image-backed A02747-1 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
CXADR Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 40 kDa observed | |
| Observed band | 40 kDa observed | |
| Gel | 12-15% | |
| Positive control | Prostate | |
| Negative control | Smooth muscle |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 40 kDa |
| ⓘ | Localization | Cell membrane / Basolateral cell membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated CXADR Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Duodenum |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A02747-1 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected CXADR Western Blot Band Size?
Use the product-observed 40 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 40 kDa | Matches the authoritative product WB observation. |
| 40 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected CXADR appearancePlan around 40 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 40 kDa; use this as the primary experimental expectation. |
| Calculated mass | 40 kDa from UniProt P78310; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A02747-1. |
| Situation | Likely cause | Next action |
|---|---|---|
| 40 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing CXADR band
A02747-1 · CXADR
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for CXADR Western blot
🧪Use Prostate as the first positive-control candidate and retain an orthogonal negative control.
Positive control: Prostate (High)
Negative control: Smooth muscle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for CXADR
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Prostate | Reported tissue cells | High | Protein (HPA) | HPA → |
| Lung | Reported tissue cells | High | Protein (HPA) | HPA → |
| Kidney | Reported tissue cells | High | Protein (HPA) | HPA → |
| Gallbladder | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cerebellum | Reported tissue cells | Low | Protein (HPA) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Smooth muscle | Reported tissue cells | Not detected | Protein (HPA) | HPA → |
Section 3
Advanced CXADR Western Blot Tips
Deeper troubleshooting and optimisation questions for CXADR, answered from its protein features.
Which band should guide the blot?
Use 40 kDa, the observation attached to the authoritative A02747-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 40 kDa expectation.
Which positive control should I start with?
Start with Prostate, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Smooth muscle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for CXADR Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A02747-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
CXADR Western Blot Reagents
Human/Mouse/Rat-reactive CXADR Western blot reagents with authoritative product imagery.
Real WB data
Anti-CXADR Antibody Picoband®
Cat # A02747-1
Real WB data
Anti-Coxsackie Adenovirus Receptor/CXADR Antibody Picoband®
Cat # PA1852
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P78310
- Human Protein Atlas — CXADR
- A02747-1 product record
- PMC6345744 — Characterization of a novel species of adenovirus from Japanese microbat and role of CXADR as its entry factor (Scientific reports, 2019)
- PMC4468136 — Podocyte-Specific Deletion of Murine CXADR Does Not Impair Podocyte Development, Function or Stress Response (PloS one, 2015)
- PMC5225458 — A novel monoclonal antibody targeting coxsackie virus and adenovirus receptor inhibits tumor growth in vivo (Scientific reports, 2017)